Joshua M Chevalier
Overview
Explore the profile of Joshua M Chevalier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen M, Han A, Chevalier J, Klock E, Pandithakoralage H, de Nooy A, et al.
PLoS One
. 2024 Oct;
19(10):e0311198.
PMID: 39365802
Places of worship serve as a venue for both mass and routine gathering around the world, and therefore are associated with risk of large-scale SARS-CoV-2 transmission. However, such routine gatherings...
2.
Hansen M, Lekodeba N, Chevalier J, Ockhuisen T, Del Rey-Puech P, Marban-Castro E, et al.
BMJ Open
. 2024 Apr;
14(4):e078852.
PMID: 38631825
Objective: Diagnostic testing is an important tool to combat the COVID-19 pandemic, yet access to and uptake of testing vary widely 3 years into the pandemic. The WHO recommends the...
3.
Chevalier J, Han A, Hansen M, Klock E, Pandithakoralage H, Ockhuisen T, et al.
BMJ Open
. 2024 Feb;
14(2):e078674.
PMID: 38417953
Objectives: To determine the most epidemiologically effective and cost-effective school-based SARS-CoV-2 antigen-detection rapid diagnostic test (Ag-RDT) self-testing strategies among teachers and students. Design: Mathematical modelling and economic evaluation. Setting And...
4.
Chevalier J, Hansen M, Coskun E, Sy K, Drakes J, Dowling S, et al.
Lancet Glob Health
. 2024 Feb;
12(3):e457-e466.
PMID: 38365416
Background: Since 2000, there has been a substantial global reduction in the vertical transmission of HIV. Despite effective interventions, gaps still remain in progress towards elimination in many low-income and...
5.
Chevalier J, Sy K, Girdwood S, Khan S, Albert H, Toporowski A, et al.
PLOS Glob Public Health
. 2023 Mar;
2(5):e0000086.
PMID: 36962136
Countries around the world have implemented restrictions on mobility, especially cross-border travel to reduce or prevent SARS-CoV-2 community transmission. Rapid antigen testing (Ag-RDT), with on-site administration and rapid turnaround time...
6.
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy
Lian X, Seiger K, Parsons E, Gao C, Sun W, Gladkov G, et al.
Cell Host Microbe
. 2023 Jan;
31(1):83-96.e5.
PMID: 36596305
HIV-1 establishes a life-long reservoir of virally infected cells which cannot be eliminated by antiretroviral therapy (ART). Here, we demonstrate a markedly altered viral reservoir profile of long-term ART-treated individuals,...
7.
Lian X, Gao C, Sun X, Jiang C, Einkauf K, Seiger K, et al.
Sci Transl Med
. 2021 Dec;
13(624):eabl4097.
PMID: 34910552
Increasing evidence suggests that durable drug-free control of HIV-1 replication is enabled by effective cellular immune responses that may induce an attenuated viral reservoir configuration with a weaker ability to...
8.
Jiang C, Lian X, Gao C, Sun X, Einkauf K, Chevalier J, et al.
Nature
. 2020 Aug;
585(7824):261-267.
PMID: 32848246
Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of infected individuals (here termed 'elite controllers'), despite the presence of a replication-competent viral reservoir. Inducing such...
9.
Lee G, Reddy K, Einkauf K, Gounder K, Chevalier J, Dong K, et al.
Nat Commun
. 2019 Jun;
10(1):2737.
PMID: 31227699
Little is known about the genotypic make-up of HIV-1 DNA genomes during the earliest stages of HIV-1 infection. Here, we use near-full-length, single genome next-generation sequencing to longitudinally genotype and...